NuCana plc has initiated an expansion study of its anti-cancer drug NUC-7738 combined with pembrolizumab for patients with melanoma resistant to PD-1 inhibitors, with initial data expected in Q4 2025 ...
Quantity, purity and quality of CTCs captured using the Parsortix system shown to be superior to an alternative antibody-based approach Study supports integration of the Parsortix system into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results